vancomycin IV
Selected indexed studies
- Reducing Vancomycin Use in a Level IV NICU. (Pediatrics, 2020) [PMID:32611807]
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. (Lancet Infect Dis, 2018) [PMID:29273269]
- The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. (Med Mal Infect, 2013) [PMID:24238896]
_Worker-drafted node — pending editorial review._
Connections
vancomycin IV is a side effect of
Sources
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. (2018) pubmed
- Reducing Vancomycin Use in a Level IV NICU. (2020) pubmed
- The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. (2013) pubmed
- Duodenal infusion of donor feces for recurrent Clostridium difficile. (2013) pubmed
- Vancomycin-associated Henoch-Schönlein purpura. (2017) pubmed
- Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. (2022) pubmed
- An updated comparison of drug dosing methods. Part IV: Vancomycin. (1991) pubmed
- Uncovering Discrepancies in IV Vancomycin Infusion Records between Pump Logs and EHR Documentation. (2022) pubmed
- Vancomycin-induced ototoxicity in very-low-birthweight infants. (2020) pubmed
- [Intraosseous vancomycin in total knee arthroplasty]. (2024) pubmed